High plasma leucine levels strongly correlate with type 2 diabetes. Studies of muscle 25 cells suggest that leucine alters the insulin response for glucose transport by 26 activating an insulin-negative feedback loop driven by the mammalian target of 27 rapamycin/p70 ribosomal S6 kinase (mTOR/p70S6K) pathway. Here, we examined 28 the molecular mechanism involved in leucine's action on cardiac glucose uptake. 
Metabolism and acetylation contribute to leucine-mediated
High plasma leucine levels strongly correlate with type 2 diabetes. Studies of muscle 25 cells suggest that leucine alters the insulin response for glucose transport by 26 activating an insulin-negative feedback loop driven by the mammalian target of 27 rapamycin/p70 ribosomal S6 kinase (mTOR/p70S6K) pathway. Here, we examined 28 the molecular mechanism involved in leucine's action on cardiac glucose uptake. 29
Leucine was indeed able to curb glucose uptake after insulin stimulation in both 30 cultured cardiomyocytes and perfused hearts. Although leucine activated 31 mTOR/p70S6K, the mTOR inhibitor rapamycin did not prevent leucine's inhibitory 32 action on glucose uptake, ruling out the contribution of the insulin-negative feedback 33 loop. α-Ketoisocaproate, the first metabolite of leucine catabolism, mimicked 34 leucine's effect on glucose uptake. Incubation of cardiomyocytes with 13 C-labeled 35 leucine ascertained its metabolism to ketone bodies (KBs), which had similar 36 negative impact on insulin-stimulated glucose transport. Both leucine and KBs 37 reduced glucose uptake by affecting translocation of the glucose transporter 4 38 (GLUT4) to the plasma membrane. Finally, we found that leucine elevated global 39 protein acetylation level. Pharmacological inhibition of lysine acetyltransferases 40 counteracted this increase in protein acetylation and prevented leucine's inhibitory 41 action on both glucose uptake and GLUT4 translocation. Taken together, these 42 results indicate that leucine metabolism into KBs contributes to inhibition of cardiac 43 glucose uptake by hampering the translocation of GLUT4-containing vesicles via 44 acetylation. They offer new insight into the establishment of insulin resistance in the 45 heart. 46
47

New and Noteworthy (50 words)Introduction 58
Several cross-sectional human studies have reported strong correlations between 59 high plasma levels of branched-chain amino acids (BCAAs), especially leucine, and 60 metabolic diseases, such as insulin resistance and type 2 diabetes (28, 38, 51) . 61
Longitudinal investigations have revealed that BCAAs have stronger predictive 62 signatures for type 2 diabetes development and cardiometabolic alterations than 63 lipids, even though lipids are well-known to participate in the occurrence of such 64 pathological events (8, 57) . Whether leucine is a simple biomarker of or a culprit in 65 this pathogenesis, or both, remains, however, an interesting question to be 66
ascertained. 67
In vitro experiments have shown that leucine interferes with glucose metabolism. It 68 inhibits insulin-stimulated glucose uptake in muscle cells through activation of the 69 insulin-negative feedback loop controlled by the mammalian target of rapamycin/p70 70 ribosomal S6 kinase (mTOR/p70S6K) pathway (56). Knowledge on insulin-signaling 71 pathways is important to understand the concept. Insulin signaling leads to the 72 activation of protein kinase B/Akt, which can phosphorylate Akt substrate of 160 kDa 73 (AS160) promoting glucose transporter 4 (GLUT4) translocation to the plasma 74 membrane responsible for glucose uptake (for review (11)). In parallel, Akt activates 75 mTOR/p70S6K, originally known to stimulate protein synthesis. However, 76 mTOR/p70S6K also phosphorylates and inhibits insulin receptor substrate-1 (IRS-1) 77 located upstream of Akt, reducing insulin signaling in a negative feedback manner 78 (52, 56) . 79
In addition to insulin, BCAAs, and particularly leucine, are potent stimulators of the 80 mTOR/p70S6K pathway and protein synthesis, especially in muscles and heart (19, 81 Phosphorylation and acetylation levels were evaluated on immunoblots of soluble cell 144 lysates. Primary antibodies against phosphorylation sites were purchased from Cell 145
Signaling: antiphospho-Thr389 p70S6K (#9234), antiphospho-Ser636/639 IRS-1 146 (#2388), antiphospho-Ser473 Akt (#4060), antiphospho-Akt substrate (for AS160 147 phosphorylation level determination) (#9611) and antiphospho-Thr172 AMP-activated 148 protein kinase (AMPK) (#2531). The acetylation profile of total soluble proteins was 149 evaluated with a primary antibody against total acetyl-lysine (Cell Signaling, #9441). 150
Total protein level was verified similarly with primary antibody against p70S6K (Cell 151 Signaling, #9202), AS160 (Cell Signaling, #07-741) and AMPK (Cell Signaling, 152 #5831), IRS-1 (Pierce, #MA5-15072), GLUT4 (Millipore, #07-1404) (Sigma-Aldrich). Labeling of all carbons of leucine allowed us to measure metabolites 165 coming from its catabolism. Cardiomyocytes, initial and final medium samples (300 166 µl) were treated with methanol 70% and analyzed by gas chromatography-mass 167 spectrometry to assess 13 C enrichment of leucine, βHB as well as citric acid cycle 168 (CAC) intermediates (citrate and malate), as described previously (31, 44) . The 169 contribution of leucine to KB formation was calculated from the precursor-product 170 13 C-enrichment ratio: M3-βHB (corresponding to βHB labeled on 3 carbons, which 171 arise from carbons 4, 5 and 6 of [U 13 -C 6 ]leucine) on M6-leucine. Leucine contribution 172 to acetyl-CoA formation (through its carbon 2 and 3) for citrate synthesis (CS), 173 corresponding to the flux ratio Leu/CS, was calculated from 13 C enrichment of the 174 acetyl moiety (C-4+5) and malate moiety (C-1+2+3+6) of citrate. Initial MPE M6 of 175 leucine in the medium has been assessed for all conditions and values of flux ratios 176
were corrected for the contribution of unlabeled leucine in medium 199. 177
Evaluation of GLUT4 translocation 178
Adenoviral construction expressing hemagglutinin (HA)-GLUT4-green fluorescent 179 protein (GFP) was kindly provided by Dr. Corley Mastick (Department of Biochemistry 180 and Molecular Biology, University of Nevada, Reno, USA) (37). GFP was fused to the 181 carboxyl-terminus of GLUT4 to track all exogenous GLUT4. In contrast, HA epitope 182 was inserted in the first exofacial loop of GLUT4, allowing the exclusive detection of 183 GLUT4 inserted into the membrane of non-permeabilized cells. Cardiomyocytes were 184 infected with HA-GLUT4-GFP adenoviruses at a multiplicity of infection of 5 for 48 h 185 (7). After paraformaldehyde 4% (vol/vol) 
Results
197
Leucine inhibits glucose uptake in adult cardiomyocytes 198
As reported previously (10, 23), 3 nM insulin increased glucose uptake by 6-fold in 199 primary cultured adult cardiomyocytes (Fig. 1A) . The impact of short-(1-h) and long-200 term (20-h) pre-incubation with 10mM leucine-supplemented medium was evaluated 201 on this insulin response as well as on the Thr389 phosphorylation state of p70S6K, 202 known to correlate with activation of the mTOR/p70S6K pathway (48, 52) ( Fig. 1A  203 and B). We showed previously that short-term exposure to leucine (30 min) increased 204 p70S6K phosphorylation and activity in cardiomyocytes, although this stimulation was 205 less potent than that induced by insulin (48). Here, we confirmed this observation 206 after 1-h treatment (Fig. 1B) . Interestingly, this short-term pre-incubation with leucine 207 increased insulin-mediated p70S6K phosphorylation. In contrast, leucine action on 208 p70S6K tended to disappear after 20-h incubation (Fig. 1B) . Its effect on glucose 209 uptake was basically the opposite. Indeed, short-term leucine exposure did not 210 impact insulin-stimulated glucose uptake, whereas long-term treatment efficiently 211 inhibited it (Fig. 1A) . In summary, these results showed a clear disconnection 212 between leucine action on p70S6K pathway and glucose uptake. 213
Knowing that 10 mM leucine, a frequently-used concentration, is supraphysiological, 214 it seemed essential to investigate the impact of a lower leucine concentration. First, a 215 dose-response curve in 199 medium revealed that a concentration of 3 mM leucine 216 also interfered with glucose uptake after a 20-h pre-incubation (Fig. 1E) . Adult 217 cardiomyocytes in culture are commonly maintained in 199 medium, which is known 218 to preserve original structure and function of such primary cells. 199 medium 219 contains basal mixture of amino-acids including leucine. This can be considered to be 220 negligible when supraphysiological concentrations of leucine such as 3 or 10 mM 221 were supplemented. However, to check if physiological concentration of leucine was 222 also able to impact glucose uptake, such medium cannot be used any more. For this 223 reason, we transferred cardiomyocytes in amino acids-free Krebs medium and 224 incubated them with physiological concentrations of leucine (Fig. 1F) . Under this 225 experimental condition, 100 and 200 µM of leucine significantly reduced the insulin-226 mediated stimulation of glucose uptake. As expected, this reduction, which 227 approximated 20%, was less important than that induced by 10 mM of leucine (Fig.  228 
1F). 229
The mTOR/p70S6K negative feedback loop is not involved in leucine-mediated 230 inhibition of glucose uptake 231
The fact that leucine differentially affected p70S6K and glucose uptake is not in line 232
with the mTOR/p70S6K-mediated negative feedback loop hypothesis. Consequently, 233
we checked leucine's action on IRS-1 phosphorylation state and downstream insulin 234 signaling via Akt phosphorylation. Parallel to p70S6K phosphorylation, short-term 235 pre-incubation with leucine increased IRS-1 phosphorylation level at its Ser636/639 236 inhibitory sites especially in presence of insulin (Fig. 1C) . Accordingly, insulin-237 dependent Akt phosphorylation was concomitantly reduced (Fig. 1D ). These 238 observations reflected clear activation of the insulin-negative feedback loop after 239 short-term pre-incubation with leucine, while glucose uptake remained unchanged, 240 reinforcing that leucine's inhibitory action was independent of mTOR/p70S6K. 241
To rule out the putative implication of mTOR/p70S6K in leucine's effect on glucose 242 uptake at long-term incubation time, we first treated cardiomyocytes with the mTOR 243 inhibitor rapamycin ( Fig. 2A-C) . In all conditions, rapamycin completely abrogated 244 p70S6K stimulation ( Fig. 2A) . This led to an increase of Akt phosphorylation in 245 agreement with the loss of the mTOR/p70S6K insulin-negative feedback loop (Fig.  246   2B ). Despite this increase in insulin signaling, rapamycin did not prevent leucine's 247 inhibitory impact on both basal and insulin-induced glucose uptake (Fig. 2C) , 248
indicating that leucine might block glucose uptake independently of insulin signaling. 249
Secondly, we evaluated leucine's impact on glucose uptake induced by the AMPK 250 activator oligomycin. Oligomycin, which increases AMP concentration by inhibiting 251 mitochondrial ATP synthase, was commonly used to activate AMPK in adult 252 cardiomyocytes (10, 23, 25, 55) . AMPK activation is known to increase AS160 253 phosphorylation and glucose uptake independently of insulin (10, 45, 55) . We 254 confirmed the stimulation of glucose uptake and phosphorylation of AMPK and 255 AS160 in response to oligomycin treatment ( Fig. 2D-F) . As for insulin-induced 256 glucose uptake, short-term pre-incubation with leucine had no impact on oligomycin-257 mediated stimulation of glucose uptake while long-term pre-incubation clearly 258 inhibited it. This inhibitory action of leucine occurred independently of upstream 259 signaling, with neither AMPK nor AS160 phosphorylation state being affected, 260
suggesting that the inhibitory mechanism of leucine on glucose uptake occurred at a 261 step downstream AS160. 262
Taken altogether, these results show that leucine blocked glucose uptake whatever 263 the stimuli and that its inhibitory role did not depend on the mTOR/p70S6K-mediated 264 negative feedback loop and, more generally, on insulin signaling. 265
Leucine metabolite α-ketoisocaproate inhibits cardiac glucose uptake 266
The involvement of insulin signaling in leucine's inhibitory action being discarded, the 267 implication of leucine metabolism was then considered. Cardiomyocytes were treated 268 with 3 nM insulin to stimulate glucose uptake after 20-h pre-incubation with either 10 269 mM of the non-metabolized leucine analog 2-aminobicyclo[2,2,1]heptane-2-270 carboxylic acid (BCH) or the first metabolite resulting from leucine catabolism, KIC 271 (Fig. 3A) . KIC efficiently reduced insulin-induced glucose uptake whereas BCH had 272 no effect. KIC also inhibited oligomycin-mediated glucose uptake (Fig. 3B) . These 273 observations demonstrate that leucine metabolism is involved in its inhibitory action. 274
Leucine is catabolized into ketone bodies and citric acid cycle intermediates in 275
cardiomyocytes 276
It is commonly accepted that leucine produces KBs in cardiomyocytes and studies 277 have shown leucine's entry into the CAC (31). However, it was important to 278 investigate leucine's catabolism in our model. For this, we incubated cardiomyocytes 279 with increasing concentrations of [U- Altogether, these results suggest the importance of leucine as an energy-providing 294 substrate for cardiomyocytes. 295
Ketone bodies mimic leucine's action on glucose uptake 296
Similarly to leucine and KIC, pre-incubation of cardiomyocytes with increasing 297 concentrations (from 0.1 to 1 mM) of AcAc and βHB, alone or in combination 298 (AcAc/βHB in a 1:5 ratio), inhibited glucose uptake progressively ( Fig. 5A-C) . 299 Strikingly, 0.3 mM of AcAc/βHB, which is within the concentration range found in the 300 plasma of diabetic patients (35), inhibited insulin-stimulated glucose uptake by 301 50.8±8.0% (p<0.01). Like leucine, AcAc/βHB acted independently of the insulin 302 signaling pathway as they also inhibited oligomycin-induced glucose uptake (Fig.  303 
5D). Leucine and ketone bodies decrease GLUT4 translocation to the plasma 304 membrane 305
Insulin-stimulated glucose uptake is governed by GLUT4 translocation (1). Under 306 basal conditions, GLUT4 is trapped in intracytoplasmic vesicles. Insulin stimulation 307 leads to the translocation of these GLUT4-containing vesicles to the plasma 308 membranes, allowing GLUT4 to transport extracellular glucose. Given that GLUT4 309 expression was not modified by either leucine or AcAc/βHB (Fig. 6A ), we investigated 310 their impact on GLUT4 translocation and insertion into the plasma membrane of 311 cardiomyocytes. We deployed an adenoviral vector encoding a fusion protein HA-312 GLUT4-GFP that has already been successfully employed for such evaluation (37) 313 ( Fig. 6B ). This construct allowed us to follow overexpressed GLUT4 pools, with GFP 314 (green staining Fig. 6C ), as well as specific GLUT4 pools inserted into the 315 cytoplasmic membrane with external HA-tag monitored by immunostaining on non-316 permeabilized cells (red staining in Fig. 6C ). 317 Different amounts of adenoviral particles were tested previously to determine the 318 level at which GLUT4 expression was monitored sufficiently but was also not too high 319 so as to prevent saturation of the GLUT4 retention machinery. Indeed, such 320 saturation would provoke the constitutive presence of GLUT4 in the plasma 321 membrane, with elevated basal glucose transport and loss of insulin response. At 322 intermediate multiplicity of infection of 5, insulin stimulated glucose uptake (data not 323 shown) whereas exogenous GLUT4 was detectable (Fig. 6C ). In this case, insulin 324 treatment induced a 2-fold increase of exogenous GLUT4 translocation to the plasma 325 membrane (Fig. 6C ). Leucine and AcAc/βHB drastically blunted insulin-induced 326 GLUT4 translocation (Fig. 6C ), suggesting that their inhibitory effect impact events 327 involved in GLUT4 translocation process. 328
Protein acetylation probably participates in leucine's action on glucose uptake 329
Acetyl-CoA is an important intermediate resulting from leucine and KBs catabolism. 330
As confirmed by our metabolic labeling study, acetyl-CoA is metabolized into the 331 CAC, which is closely related to energy metabolism. However, acetyl-CoA can also 332 be used by acetyltransferases to acetylate proteins (17), a post-translational 333 modification taking a great importance in the regulation of metabolism (61). We 334 hypothesized that part of acetyl-CoA, resulting from leucine catabolism, might be 335 rerouted to augment protein acetylation and that one/some of these acetylated 336 proteins might control glucose uptake. We first showed that leucine treatment 337 promoted the increase of acetylation profile of cardiac soluble proteins (Fig. 7A-B) . 338
Next, we pre-treated cardiomyocytes with garcinol, a commonly-used inhibitor of 339 acetyltransferases (5). Garcinol treatment prevented the increase of protein 340 acetylation induced by leucine (Fig. 7A-B ) and, remarkably, fully reversed the 341 leucine-mediated inhibition of glucose uptake (Fig. 7C) . Similar data were obtained 342 with anacardic acid, another acetyltransferases inhibitor (6) ( Fig. 7D-F) , implicating 343 acetylation in leucine-mediated regulation of glucose uptake. Finally, we evaluated 344 the effect of acetyltransferases inhibitors on the impact of leucine on HA-GLUT4-GFP 345 translocation (Fig. 8) . In line with data obtained on glucose uptake, both garcinol and 346 anacardic acid prevented the inhibition of HA-GLUT4-GFP translocation induced by 347 leucine, suggesting that acetylation is implicated in the regulation of GLUT4-348 containing vesicles trafficking. 349
Leucine and ketone bodies inhibit insulin-stimulated glucose uptake in perfused 350
hearts 351
To impose more physiological conditions, the action of leucine and its metabolites on 352 glucose uptake was also tested in an ex vivo perfused heart model. As described 353 previously (46), insulin doubled glucose uptake (Fig. 9A-D) . This stimulation was 354 inhibited by leucine ( Fig. 9A and C Our data demonstrate that leucine inhibits glucose uptake in adult cardiomyocytes as 368 well as in perfused hearts, by decreasing GLUT4 translocation to the plasma 369 membrane. Our data further indicate that this follows leucine catabolism into KBs, 370 which fully mimic its inhibitory effect. Inhibition affects both basal and insulin-371 stimulated glucose uptake. In opposition to what has been described in muscle cells, 372
we rule out implication of the mTOR/p70S6K-mediated insulin-negative feedback 373 loop in leucine's inhibitory action. In contrast, we propose the involvement of 374 acetylation processes. These original observations provide an important piece of the 375 puzzle, recapitulating the mechanisms by which leucine, an early marker of diabetes 376 (8, 38, 51), regulates glucose uptake. 377
Leucine inhibits glucose uptake independently of insulin signaling 378
The following data demonstrate that leucine-induced inhibition of glucose uptake is 379 not mediated by the mTOR/p70S6K pathway. First, 1-h treatment with leucine exerts 380 its action on signaling with changes not only in the p70S6K phosphorylation state but 381 also in IRS-1, Akt and AS160, without any impact on glucose transport. Second, 382 rapamycin, a potent mTOR inhibitor, does not reverse the inhibitory action of 20-h 383 leucine treatment on glucose uptake. Third, long-term leucine incubation similarly 384 inhibits glucose uptake induced by the AMPK pathway, demonstrating that its action 385 extends beyond insulin's action. Accordingly, it must be mentioned that leucine's 386 inhibitory action at long-term exposure was similarly observed on basal glucose 387 uptake. Consequently, the amplitude of stimulation promoted by insulin was not 388 affected per se (6.3±1.4 vs. 6.1±0.5-fold increase for leucine vs. control, respectively, 389 non-significant). 390
The discrepancy between the impact of leucine on insulin signaling and glucose 391 transport in cardiac cells is the first salient message deriving from our work and 392 questions the relative role of the insulin-negative feedback loop compare to a control 393 by protein acetylation of GLUT4 translocation in leucine's inhibitory action on glucose 394 uptake in the whole body. A difference between those two regulatory mechanisms 395 seems to be observed between skeletal muscle cells and cardiomyocytes in 396 response to leucine elevation, in line with other differences observed between 397 muscles and heart. Indeed, previous work discerned a protective effect of AMPK 398 activation on leucine-induced insulin resistance in muscles (47), a phenomenon 399 incompatible with our AMPK data. 400
Leucine's inhibitory action is mediated by its catabolism 401
We confirmed, using Hue's and Taegtmeyer's groups (27, 46) and has also been updated very recently in 412 athletes who received ketone ester-based drinks (18). In these different studies, both 413 glucose uptake and/or glycolysis were inhibited by KBs. One may wonder whether 414 glucose uptake might not be simply inhibited in response to accumulation of 415 intermediates of glucose metabolism due to glycolysis inhibition as represented by 416
Randle and colleagues (42). In particular, glucose-6-phosphate is known to inhibit 417 hexokinase that could subsequently increase intracellular glucose concentrations, 418 reducing GLUT4 activity in the plasma membrane. However, leucine did not augment 419 glucose-6-phosphate concentration (data not shown). It has been reported that 420 intrinsic GLUT4 activity can be regulated by protein-protein interactions once inserted 421 in the plasma membrane (60). However, such regulation cannot explain our 422 observations. Indeed, our study demonstrates that both leucine and KBs act 423 upstream by inhibiting GLUT4 translocation, preventing its insertion into the plasma 424 membrane. 425
Several groups have suggested a role of insulin and AMPK signaling in the inhibitory 426 action of KBs on cardiac glucose uptake (40, 41, 53) . In these works, depending on 427 the stimulus, the molecular mechanism proposed to be involved is inhibition of insulin 428 signaling or of AMPK activation. According to our data, they may not seem accurate 429 explanations. We ruled out the involvement of insulin signaling in the first part of the 430 work. Moreover, AMPK activation is preserved in the presence of leucine or its 431 downstream metabolites. 432
As per our data, we propose the involvement of protein acetylation (Fig. 9F) . Acetyl-433
CoA derived from leucine catabolism (3 acetyl-CoAs per leucine molecule) can be 434 converted to citrate and enter the CAC to produce energy, but can also be 435 metabolized by acetyltransferases in the mitochondria or in the cytosol after its 436 indirect cytosolic transfer to acetylate lysine in proteins (17). Our data showed that 437 both events occur under leucine treatment. Strikingly, treatment with inhibitors of 438 acetyltransferases prevents the increase in protein acetylation and reverses glucose 439 uptake inhibition as well as reduction in GLUT4 translocation induced by leucine. 440
According to these observations, it is tempting to speculate that acetylation targets 441 events involved in GLUT4 trafficking process rather than GLUT4 itself. In agreement, 442 Leucine was shown to be metabolized into KBs, and both leucine and KBs had 458 similar effects on decreasing glucose uptake. While this association certainly 459 supports the notion that it is the KBs produced from leucine that inhibit glucose 460 uptake, genetic evidence still need to be provided to prove that leucine effect is 461 entirely due to KB production. A similar genetic evidence would re-inforce the 462 implication of acetylation process in this paradigm. 463
We observed, in our ex vivo perfused heart model, that leucine, KIC and KBs 464 drastically inhibited glucose uptake. This model requires shorter pre-incubation time 465 to induce this inhibition, in the range of minutes compared to hours for 466 cardiomyocytes in vitro. This difference in time course between perfused hearts and 467 resting cardiomyocytes could come from differences in energy requirements between 468 the 2 models and reinforces the fact that metabolism might be involved in leucine's 469
effect. 470
Both in vitro and ex vivo experiments were intentionally performed in absence of fatty 471 acids in the goal of preventing any interference of this additional substrate. It will be 472 of great interest to evaluate the impact of fatty acids on leucine and KB action on 473 glucose uptake in a future study. 474
Leucine concentrations in our models (millimolar range) are similar to those generally 475 used in other studies in the scientific literature (3, 19, 24, 48, 56 ). However, it should 476 be noted that they are far from physiological concentrations. Healthy subjects are 477 characterized by plasma leucine/isoleucine concentrations around 140 µM (39, 54) . 478 This level has been shown to be increased in different situations, including particular 479 food intake and pathological conditions linked to type 2 diabetes. Indeed, due to 480 modification of dietary habits, average leucine intake has almost tripled since the end 481 of the Second World War (36). Feeding animals with BCAA-enriched diets can result 482 in a 300% increase of leucine plasma level (39). Moreover, animal and human 483 models of obesity and diabetes are characterized by chronically-elevated plasma 484 leucine/isoleucine concentrations reaching up to 250 µM (21, 38, 49, 51) . Our data 485 showed that leucine's impact on the insulin response is dose-dependent with total 486 suppression of the insulin response at 10 mM but more modest inhibition at 100 µM. 487
We postulate that the increased leucine levels encountered in human situations, like 488 diabetes, might lead to similar, modest inhibition. Even if moderate, such decreased 489 insulin responses would certainly affect cardiac metabolic flexibility. 490
Conclusions 491
Results from this study unravel a molecular mechanism that explains the inhibition of 492 glucose uptake by leucine and KBs via increased protein acetylation. This 493 mechanism could participate in the establishment of metabolic inflexibility and loss of 494 glucose utilization seen in the hearts of type 2 diabetic patients, such metabolic 495 inflexibility participating in deterioration of cardiac function (13, 14 
